非心源性缺血性卒中及短暂性脑缺血发作患者的抗血小板治疗

在脑血管病患者中，约80%为缺血性卒中患者，多伴有多种危险因素，是卒中复发的高危人群。在非心源性缺血性卒中/短暂性脑缺血发作（transient ischemic attack，TIA）的二级预防中，抗血小板治疗的疗效已被大量临床研究证实，并被各国的指南所推荐。本文结合新近发表的指南以及经典的临床试验，对非心源性缺血性卒中/TIA的抗血小板治疗模式做一综述。

Antiplatelet Therapy for Ischemic Stroke or Transient Ischemic Attack of Non-Cardiac Origin

In all patients with cerebrovascular disease, ischemic stroke accounts for about 80%. Moreover, ischemic stroke patients, many of whom accompanied by multiple risk factors suffer high risk of stroke recurrence. In the secondary prevention of non-cardiac ischemic stroke / transient ischemic attack （TIA）, the efficacy of anti-platelet therapy has been verified by a large number of clinical studies, and was recommended by national guidelines of many countries. According to recent guideline and classical clinical trials, we make a review about the model of antiplatelet therapy for ischemic stroke or TIA of non-cardiac origin.